Bill > HB3192

This bill provides an additional $4 million from the General Fund to the Oregon Health Authority (OHA) for the 2025-2027 biennium to expand newborn bloodspot screening to include five specific rare genetic and congenital diseases. The newly added screening conditions are: Mucopolysaccharidosis type II (MPS II), which is a rare genetic disorder affecting multiple body systems; Guanidinoacetate methyltransferase deficiency (GAMT), a metabolic disorder that can cause intellectual disabilities; Krabbe disease, a rare and often fatal genetic disorder affecting the nervous system; Duchenne muscular dystrophy, a progressive muscle-weakening genetic condition primarily affecting males; and Cytomegalovirus (CMV), a common viral infection that can cause serious health problems in newborns. The funding will be used through the Northwest Regional Newborn Bloodspot Screening Program to test newborns for these conditions, which could enable earlier detection and potential intervention or treatment.

Budget and Finance, Health and Social Services

https://olis.oregonlegislature.gov/liz/2025R1/Measures/Overview/HB3192